Evogene Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Evogene hat ein Gesamteigenkapital von $12.2M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $40.1M bzw. $27.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$19.95m
Eigenkapital	US$12.24m
Gesamtverbindlichkeiten	US$27.88m
Gesamtvermögen	US$40.11m

Jüngste Berichte zur Finanzlage

Recent updates

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Mar 05

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Oct 09

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Jun 26

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Mar 13

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Oct 07

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Jun 16

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Mar 02

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

May 28

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

Jan 21

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Nov 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: EVGNDie kurzfristigen Aktiva des Unternehmens ($25.4M) übersteigen seine kurzfristigen Passiva ($23.3M).

Langfristige Verbindlichkeiten: EVGNDie kurzfristigen Vermögenswerte des Unternehmens ($25.4M) übersteigen seine langfristigen Verbindlichkeiten ($4.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: EVGN ist schuldenfrei.

Schulden abbauen: EVGN hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: EVGN hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: EVGN hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 5.9% pro Jahr abnimmt

Evogene Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022)

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022)

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022)

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021)

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021)

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021)

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day high: ₪25.00

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

New 90-day high: ₪19.10

New 90-day high: ₪14.94

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

First half earnings released

New 90-day high - ₪9.46

New 90-day high - ₪5.63

New 90-day high - ₪4.17

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen